Celularity Inc (CELU)

NASDAQ
Currency in USD
Disclaimer
2.510
-0.020(-0.79%)
Closed
After Hours
2.650+0.140(+5.578%)
CELU Scorecard
Full Analysis
Operates with a significant debt burden
Unusual Post-Market activity
Fair Value
Day's Range
2.4002.640
52 wk Range
1.5907.970
Prev. Close
2.53
Open
2.55
Day's Range
2.4-2.64
52 wk Range
1.59-7.97
Volume
38,064
Average Volume (3m)
14,365
1-Year Change
-15.66%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
CELU Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Celularity Inc Company Profile

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. The company operates through Cell Therapy, Degenerative Disease, and BioBanking segments. Its lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn’s disease. In addition, the company is developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. Celularity Inc. produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is based in Florham Park, New Jersey.

Compare CELU to Peers and Sector

Metrics to compare
CELU
Peers
Sector
Relationship
P/E Ratio
−0.3x−1.9x−0.6x
PEG Ratio
0.000.000.00
Price/Book
1.3x2.2x2.6x
Price / LTM Sales
2.4x8.1x3.2x
Upside (Analyst Target)
-408.8%44.2%
Fair Value Upside
Unlock31.3%7.9%Unlock

People Also Watch

7.61
LUNR
+5.26%
3.180
SEED
+5.65%
0.582
HEPA
-1.68%
5.280
RVNC
+0.38%
1.790
MFH
+7.19%

FAQ

What Is the Celularity (CELU) Stock Price Today?

The Celularity (CELU) stock price today is 2.51. Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell. . The dividend yield is

What Stock Exchange Does Celularity Trade On?

Celularity is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Celularity?

The stock symbol for Celularity is "CELU."

What Is the Celularity Market Cap?

As of today, Celularity market cap is 55.18M.

What is Celularity Earnings Per Share?

The Celularity EPS is -11.02.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2024 - Fusion Media Limited. All Rights Reserved.